GE HealthCare Technologies Inc. logo

GE HealthCare Technologies Inc. (GEHC)

Market Closed
5 Dec, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
85. 46
+2.94
+3.56%
$
36.83B Market Cap
28.36 P/E Ratio
0.12% Div Yield
4,373,917 Volume
4.3 Eps
$ 82.52
Previous Close
Day Range
82.54 85.54
Year Range
57.65 94.8
Want to track GEHC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 68 days
GEHC Stock May Gain Following the Launches of Aurora and Clarify DL

GEHC Stock May Gain Following the Launches of Aurora and Clarify DL

GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.

Zacks | 1 year ago
GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL

GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL

GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.

Zacks | 1 year ago
GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging

GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging

GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.

Zacks | 1 year ago
GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care

GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care

The latest collaboration aims to provide new opportunities to improve cancer diagnosis using GE HealthCare's technology and enhance clinical workflow.

Zacks | 1 year ago
GEHC Stock May Gain Following the Launch of Pristina Via System

GEHC Stock May Gain Following the Launch of Pristina Via System

GE HealthCare announces the Pristina Via mammography system, which will help minimize repetitive tasks and streamline workflows for mammography technologists.

Zacks | 1 year ago
GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio

GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio

GE HealthCare announces the latest application additions to its OEC 3D mobile CBCT C-arm portfolio to improve clinician workflow and visualization during endoscopic bronchoscopy procedures.

Zacks | 1 year ago
GE HealthCare Guidance Was Good. The Stock Dropped Anyway.

GE HealthCare Guidance Was Good. The Stock Dropped Anyway.

GE HealthCare hosted an analyst event on Thursday. Solid guidance fell on deaf ears.

Barrons | 1 year ago
GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects

GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects

GE HealthCare's Portrait Mobile solution will provide continuous monitoring in post-surgery settings. It will also deliver informative alarms, advancing patient care while alleviating the burdens faced by clinicians.

Zacks | 1 year ago
GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging

GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging

GEHC and DeepHealth collaborate to develop AI-based imaging tools that can streamline workflow and help manage large imaging volumes without compromising diagnostic accuracy.

Zacks | 1 year ago
GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System

GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System

GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.

Zacks | 1 year ago
Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock

Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
GE HealthCare: Light Up With Growth Indicators In Medical Tech, While Undervalued

GE HealthCare: Light Up With Growth Indicators In Medical Tech, While Undervalued

GE Healthcare Technologies gets a buy rating, agreeing with today's Wall Street and SA analyst consensus. The firm's recent Q3 results showed growth indicators in multiple segments, despite headwinds from China, and will be crucial in supplying in-demand contrast dyes used in medical imaging. The stock is still undervalued on multiple fronts (EV/EBITDA, P/E), despite the share price trending above its moving average.

Seekingalpha | 1 year ago
Loading...
Load More